 We need better epidemiology, and that is for sure, so that we really do know the extent of people's use, what circumstances they're using, how they got the drug, and what they know about what they're even taking. There's not yet much evidence about the risks and benefits of microdosing, especially in the case of psilocybin. Kilmer at RAND says the market for cannabis is very different than psychedelics, but he does see parallels to where cannabis was a decade ago.